Monoclonal antibodies against MERS coronavirus show promise in phase 1 NIH-sponsored trial
Credit: NIAID and Colorado State University WHAT: A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe when administered simultaneously to healthy adults. The experimental mAbs, REGN3048 and REGN3051, target the MERS coronavirus (MERS CoV) spike protein used by the virus to attach to and infect target cells. The mAbs w...
New York United States College Park Annea Oplinger University Of Maryland National Institute Of Allergy
Source: eurekalert.org